应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
03692 翰森制药
休市中 11-20 16:08:29
30.740
-1.680
-5.18%
最高
32.100
最低
30.600
成交量
1,305万
今开
31.780
昨收
32.420
日振幅
4.63%
总市值
1,864亿
流通市值
1,864亿
总股本
60.64亿
成交额
4.05亿
换手率
0.22%
流通股本
60.64亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
翰森制药:创新药氘索昔替尼片上市申请获受理
财中社 · 11-20 18:50
翰森制药:创新药氘索昔替尼片上市申请获受理
翰森制药(03692)氘索昔替尼片上市许可申请获NMPA受理
公告速递 · 11-20 18:36
翰森制药(03692)氘索昔替尼片上市许可申请获NMPA受理
瑞银:国家医保目录谈判成功率维持高位 1类创新药创新高
智通财经 · 11-16
瑞银:国家医保目录谈判成功率维持高位 1类创新药创新高
异动解读|翰森制药盘中下跌3.02%,医保新增适应症与欧盟审评进展落地
行情直击 · 11-16
异动解读|翰森制药盘中下跌3.02%,医保新增适应症与欧盟审评进展落地
翰森制药(03692.HK):阿美替尼上市许可获欧洲药品管理局人用药品委员会积极意见
智通财经 · 11-15
翰森制药(03692.HK):阿美替尼上市许可获欧洲药品管理局人用药品委员会积极意见
翰森制药(03692):阿美替尼上市许可获欧洲药品管理局人用药品委员会积极意见
智通财经 · 11-15
翰森制药(03692):阿美替尼上市许可获欧洲药品管理局人用药品委员会积极意见
翰森制药(03692)已上市创新药所有获批适应症均已纳入医保目录
智通财经 · 11-15
翰森制药(03692)已上市创新药所有获批适应症均已纳入医保目录
翰森制药(03692)多款创新药新增及续约纳入2026年国家医保目录
公告速递 · 11-15
翰森制药(03692)多款创新药新增及续约纳入2026年国家医保目录
翰森制药(03692)阿美替尼获EMA人用药品委员会积极意见
公告速递 · 11-15
翰森制药(03692)阿美替尼获EMA人用药品委员会积极意见
翰森制药附属与昂心生物达成合作开发协议 获AI平台以发现新型口服环肽候选药物
财中社 · 11-13
翰森制药附属与昂心生物达成合作开发协议 获AI平台以发现新型口服环肽候选药物
翰森制药(03692.HK)获准使用昂心生物AI平台 最高支付可达3.17亿元
公告速递 · 11-13
翰森制药(03692.HK)获准使用昂心生物AI平台 最高支付可达3.17亿元
翰森制药(03692.HK)与昂心生物订立合作开发协议
智通财经 · 11-13
翰森制药(03692.HK)与昂心生物订立合作开发协议
花旗:翰森制药(03692.HK)阿美乐销售料持续增长 维持“买入”评级 目标价52港元
智通财经 · 11-13
花旗:翰森制药(03692.HK)阿美乐销售料持续增长 维持“买入”评级 目标价52港元
中国女首富夫妻各有千亿家业,39岁独生女接谁的班 | 棱镜
棱镜 · 11-06
中国女首富夫妻各有千亿家业,39岁独生女接谁的班 | 棱镜
异动解读|翰森制药盘中上涨3.05%,罗氏ADC合作与临床进展持续催化
行情直击 · 11-05
异动解读|翰森制药盘中上涨3.05%,罗氏ADC合作与临床进展持续催化
翰森制药10月无新增发行或股份变动
公告速递 · 11-02
翰森制药10月无新增发行或股份变动
【券商聚焦】中信证券:国内医药板块业绩持续修复
金吾财讯 · 11-02
【券商聚焦】中信证券:国内医药板块业绩持续修复
异动解读|翰森制药盘中上涨3.3%,创新药板块走强叠加ADC出海逻辑获关注
行情直击 · 10-29
异动解读|翰森制药盘中上涨3.3%,创新药板块走强叠加ADC出海逻辑获关注
异动解读|翰森制药盘中上涨3.02%,创新药板块走强叠加ADC出海逻辑获关注
行情直击 · 10-28
异动解读|翰森制药盘中上涨3.02%,创新药板块走强叠加ADC出海逻辑获关注
创新药概念板块走强 恒瑞医药(01276)涨超11% 券商看好ADC、双抗等出海赛道
金吾财讯 · 10-28
创新药概念板块走强 恒瑞医药(01276)涨超11% 券商看好ADC、双抗等出海赛道
加载更多
公司概况
公司名称:
翰森制药
所属市场:
SEHK
上市日期:
--
主营业务:
翰森制药集团有限公司是一家主要从事一系列药品的研发、生产及销售的投资控股公司。该公司的创新药产品包括阿美乐、豪森昕福、迈灵达、孚来美、恒沐、昕越、圣罗莱等产品。该公司的创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统(CNS)疾病、代谢及其他治疗领域。该公司主要在国内市场开展业务。
发行价格:
--
{"stockData":{"symbol":"03692","market":"HK","secType":"STK","nameCN":"翰森制药","latestPrice":30.74,"timestamp":1795162109008,"preClose":32.42,"halted":0,"volume":13053670,"delay":0,"changeRate":-0.051819864281307935,"floatShares":6064000000,"shares":6064000000,"eps":0.93,"marketStatus":"休市中","change":-1.68,"latestTime":"11-20 16:08:29","open":31.78,"high":32.1,"low":30.6,"amount":405045726,"amplitude":0.046268,"askPrice":30.74,"askSize":32000,"bidPrice":30.68,"bidSize":58000,"shortable":3,"etf":0,"ttmEps":1.278789,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1795397400000},"marketStatusCode":7,"adr":0,"listingDate":1560441600000,"exchange":"SEHK","adjPreClose":32.42,"dividendRate":0.016203,"openAndCloseTimeList":[[1795138200000,1795147200000],[1795150800000,1795161600000]],"volumeRatio":1.6479008590551094,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"HSP.HK","impliedVol":0.433,"impliedVolPercentile":0.2222},"requestUrl":"/m/hq/s/03692","defaultTab":"news","newsList":[{"id":"2684156735","title":"翰森制药:创新药氘索昔替尼片上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2684156735","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684156735?lang=zh_cn&edition=full","pubTime":"2026-11-20 18:50","pubTimestamp":1795171800,"startTime":"0","endTime":"0","summary":"11月20日,翰森制药(03692)发布公告,公司创新药氘索昔替尼片(HS-10374片)上市许可申请获中国国家药品监督管理局(NMPA)受理。公告指出,氘索昔替尼片是一款公司自主研发的酪氨酸激酶2(TYK2)选择性变构抑制剂,用于中重度斑块状银屑病成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611203936241268.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611203936241268.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06978","LNGR","MEDX","BK1574","BK1589","03692","BK1191","159992","BK1583","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182352892","title":"翰森制药(03692)氘索昔替尼片上市许可申请获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1182352892","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182352892?lang=zh_cn&edition=full","pubTime":"2026-11-20 18:36","pubTimestamp":1795170986,"startTime":"0","endTime":"0","summary":"2026年11月20日,翰森制药集团有限公司(03692)发布自愿公告称,其自主研发的氘索昔替尼片(HS-10374片)上市许可申请已获中国国家药品监督管理局受理,拟用于治疗中重度斑块状银屑病成人患者。\n公告显示,氘索昔替尼片为翰森制药自主研发的酪氨酸激酶2(TYK2)选择性变构抑制剂。\n上述公告由翰森制药董事会发布,董事会成员包括主席兼执行董事钟慧娟、执行董事孙远及吕爱锋博士,以及独立非执行董事林国强、陈尚伟、杨东涛和严嘉。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683699366","title":"瑞银:国家医保目录谈判成功率维持高位 1类创新药创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2683699366","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683699366?lang=zh_cn&edition=full","pubTime":"2026-11-16 16:01","pubTimestamp":1794816106,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,瑞银发布研报称,国家医保局公布2026年国家医保药品目录及商业保险创新药目录,在124个经审查的谈判或竞价候选药品中,107个获纳入医保目录,另有34个因临床替代及供应等因素被调出,令医保目录涵盖药品总数增至3,331个,同比增长2.4%,国家医保目录谈判成功率维持高位。该行指出,107个新纳入药品中有51个为1类创新药,占新增药品总数近一半,创历史新高;商业保险创新药目录的12个谈判药品亦全部获纳入。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1523605.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YS42.EUR","LU1008478684.HKD","BK1515","LU1152091168.USD","LU1951186391.HKD","LU1226288253.USD","IBBQ","LU1960683339.HKD","LU0314109678.HKD","LU1226287529.USD","BK1593","LU1226287875.USD","IE0008368742.USD","LU1226287792.SGD","LU1813983027.USD","159992","LU0067412154.USD","BK1583","LU1152091754.HKD","LU0072913022.USD","LU0315179316.USD","LU2039709279.SGD","03692","LU1328277881.USD","BK1521","LU0140636845.USD","BK1574","IE00BZ08YR35.GBP","IE00B543WZ88.USD","01530","IE0008369823.USD","LU0501845795.SGD","IE00B031HY20.USD","IE00B5MMRT66.SGD","LNGR","LU0326950275.SGD","LU0880133367.SGD","KURE","BK1589","HK0000165453.HKD","06978","IE00BZ08YT58.USD","LU1226288170.HKD","MEDX","01093","SG9999004220.SGD","BK1191","02096","01177","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135362004","title":"异动解读|翰森制药盘中下跌3.02%,医保新增适应症与欧盟审评进展落地","url":"https://stock-news.laohu8.com/highlight/detail?id=1135362004","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135362004?lang=zh_cn&edition=full","pubTime":"2026-11-16 09:52","pubTimestamp":1794793965,"startTime":"0","endTime":"0","summary":"11月16日,翰森制药盘中下跌3.02%,报33.38港元,成交额5627.7万港元。消息面上,公司日前披露,阿美乐新增一项适应症、昕越新增两项适应症纳入新版国家医保目录,自1月1日起实施;同时阿美替尼于11月12日获欧洲药品管理局人用药品委员会积极意见,建议授予欧盟上市许可。公告显示,公司已上市创新药所有获批适应症均已纳入医保目录,有助提升患者可及性;阿美替尼欧盟上市许可仍待欧盟委员会最终批准。利好落地后,股价盘中走弱。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"翰森制药盘中下跌,医保与欧盟进展落地","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683659189","title":"翰森制药(03692.HK):阿美替尼上市许可获欧洲药品管理局人用药品委员会积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2683659189","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683659189?lang=zh_cn&edition=full","pubTime":"2026-11-15 18:51","pubTimestamp":1794739907,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1583","03692","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683591866","title":"翰森制药(03692):阿美替尼上市许可获欧洲药品管理局人用药品委员会积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2683591866","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683591866?lang=zh_cn&edition=full","pubTime":"2026-11-15 18:51","pubTimestamp":1794739907,"startTime":"0","endTime":"0","summary":"智通财经APP讯,翰森制药(03692)公布,于2026年11月12日,欧洲药品管理局 (EMA)人用药品委员会(CHMP)采纳了一项积极意见,建议授予阿美替尼上市许可,用于治疗非小细胞肺癌。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1523335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK1583","BK1191","IPOS","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683659954","title":"翰森制药(03692)已上市创新药所有获批适应症均已纳入医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2683659954","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683659954?lang=zh_cn&edition=full","pubTime":"2026-11-15 18:45","pubTimestamp":1794739531,"startTime":"0","endTime":"0","summary":"智通财经APP讯,翰森制药 公布,集团创新药阿美乐新增一项适应症、昕越新增两项适应症成功纳入新版《国家基本医疗保险、工伤保险和生育保险药品目录》,新版国家目录将于2027年1月1日正式实施。集团已上市创新药所有获批适应症均已纳入医保目录,有助于进一步提高各创新药在患者中的可负担性和可及性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1523332.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","06978","IPOS","LNGR","MEDX","BK1583","BK1161","BK1191","IBBQ","BK1589","BK1574","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151472208","title":"翰森制药(03692)多款创新药新增及续约纳入2026年国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=1151472208","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151472208?lang=zh_cn&edition=full","pubTime":"2026-11-15 18:32","pubTimestamp":1794738725,"startTime":"0","endTime":"0","summary":"2026年11月15日,翰森制药集团有限公司公布,其多款创新药物及相关新增适应症被纳入《国家基本医疗保险、工伤保险和生育保险药品目录》,该目录将自2027年1月1日起实施。公告指出,翰森制药已上市的全部创新药及其已获批的所有适应症均进入或续约国家医保目录,有望进一步提升患者的可负担性与药品可及性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185048848","title":"翰森制药(03692)阿美替尼获EMA人用药品委员会积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=1185048848","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185048848?lang=zh_cn&edition=full","pubTime":"2026-11-15 18:32","pubTimestamp":1794738723,"startTime":"0","endTime":"0","summary":"2026年11月15日,翰森制药集团有限公司(03692)公布,其研发的阿美替尼(海外商品名:Aumseqa®)已于2026年11月12日获得欧洲药品管理局(EMA)人用药品委员会(CHMP)关于授予欧盟上市许可的积极意见,适应症为治疗非小细胞肺癌。\n根据公告,阿美替尼的上市许可仍须取得欧盟委员会(EC)的最终批准。公司提醒股东及潜在投资者在买卖公司股份时保持审慎。\n截至本公告日,公司董事会成员包括:主席兼执行董事钟慧娟女士,执行董事孙远女士及吕爱锋博士;独立非执行董事林国强先生、陈尚伟先生、杨东涛女士及严嘉先生。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683257254","title":"翰森制药附属与昂心生物达成合作开发协议 获AI平台以发现新型口服环肽候选药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2683257254","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683257254?lang=zh_cn&edition=full","pubTime":"2026-11-13 18:57","pubTimestamp":1794567420,"startTime":"0","endTime":"0","summary":"11月13日,翰森制药(03692)发布公告,全资附属公司翰森(上海)健康科技有限公司与昂心生物有限公司签订合作开发协议。根据协议,公司获得一项在该协议范围内使用昂心生物的AI平台以发现新型口服环肽候选药物的许可。公司将有权选择靶点、获得相应项目的知识产权及主导后续开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611133930806110.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611133930806110.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CHAT","ARTY","BK1191","QTOC","03692","BK1589","VTHR","BK1583","AIPO","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175848638","title":"翰森制药(03692.HK)获准使用昂心生物AI平台 最高支付可达3.17亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1175848638","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175848638?lang=zh_cn&edition=full","pubTime":"2026-11-13 18:35","pubTimestamp":1794566130,"startTime":"0","endTime":"0","summary":"翰森制药11月13日公告,其全资附属公司翰森(上海)健康科技有限公司已与昂心生物有限公司签署合作开发协议。根据协议,翰森制药将获许可在协议范围内使用昂心生物的AI平台,以发现新型口服环肽候选药物。翰森制药拥有靶点选择、相关项目知识产权获取及后续开发主导权。公司提醒股东及潜在投资者在买卖公司股份时保持审慎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683710571","title":"翰森制药(03692.HK)与昂心生物订立合作开发协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2683710571","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683710571?lang=zh_cn&edition=full","pubTime":"2026-11-13 18:33","pubTimestamp":1794566016,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1583","BK1589","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683952657","title":"花旗:翰森制药(03692.HK)阿美乐销售料持续增长 维持“买入”评级 目标价52港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2683952657","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683952657?lang=zh_cn&edition=full","pubTime":"2026-11-13 13:41","pubTimestamp":1794548488,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1191","BK1589","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681539988","title":"中国女首富夫妻各有千亿家业,39岁独生女接谁的班 | 棱镜","url":"https://stock-news.laohu8.com/highlight/detail?id=2681539988","media":"棱镜","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681539988?lang=zh_cn&edition=full","pubTime":"2026-11-06 15:59","pubTimestamp":1793951940,"startTime":"0","endTime":"0","summary":"但夫妻二人各自担任一家企业的董事长,各自登台为自己企业IPO敲锣,实属罕见。39岁独生女,接父母谁的班?这一年,她28岁。在官方发布的新闻稿中,代表公司对外发声的,是39岁的执行董事孙远。截至最新公告,岑均达在英属维京群岛的家族信托,持有翰森制药15.16%的股权,仅次于钟慧娟母女的Sunrise信托。这一年,她35岁。获奖人名单中,位列第二、第三的,分别是岑均达和吕爱锋。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA3MTY0MTQzNg==&mid=2650277745&idx=1&sn=56433cc41a7d89b7a6772130460005f5&chksm=864e3b8937a1c9bbd230f779eccbf19ab29c1499c71d9ab272121fc03810033c262b024efc28&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU1064130708.USD","01276","LU1997244956.HKD","LU2097828474.EUR","600276","LU1064131003.USD","BK0012","LU2495084118.USD","LU0359202008.SGD","IPOS","LU2097828714.EUR","LU2488822045.USD","03692","LU2543165471.USD","LU1969619763.USD","LU1997245094.SGD","LU0405327148.USD","BK0183","BK1589","LU2328871848.SGD","LU1820825898.SGD","LU2580892862.HKD","LU0359201612.USD","LU2097828557.USD","LU2148510915.USD","LU1781817850.SGD","LU1146622755.USD","LU1023057109.AUD","BK0188","LU1255011170.USD","LU1655091616.SGD","LU0359201885.HKD","BK0060","BK1583","LU2097828805.USD","LU1997245177.USD","LU1580142542.USD","LU2289578879.USD","LU2580892789.USD","LU1328615791.USD","BK1191","LU0405327494.USD","BK0239","LU2097828631.EUR","BK0028","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150826710","title":"异动解读|翰森制药盘中上涨3.05%,罗氏ADC合作与临床进展持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1150826710","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150826710?lang=zh_cn&edition=full","pubTime":"2026-11-05 14:50","pubTimestamp":1793861457,"startTime":"0","endTime":"0","summary":"11月5日,翰森制药盘中上涨3.05%,报35.16港元,成交额3.41亿港元。近日公司股价催化主要来自创新药出海与研发进展。公司此前与罗氏达成ADC战略合作及许可协议,潜在交易总额超155亿美元,包括4亿美元首付款、1.1亿美元一周年付款及潜在超150亿美元里程碑付款,市场将其视为ADC平台能力获全球药企验证。同时,机构近期维持买入观点,认为Mo-Rez在铂耐药卵巢癌更新数据及HS-20122一期数据表现正面,支持后续全球三期开发推进,进一步强化公司创新药国际化兑现预期。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰森制药上涨,罗氏ADC合作催化","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183881167","title":"翰森制药10月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1183881167","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183881167?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:17","pubTimestamp":1793611060,"startTime":"0","endTime":"0","summary":"2026年11月2日,翰森制药集团有限公司披露了截至2026年10月31日止月份的证券变动月报。报告显示,截至10月底,公司法定股本总额维持在20,000,000,000股,面值为每股0.00001港元,合计约200,000港元,与上月底无变化。报告期内,公司普通股已发行股本总数为6,064,150,070股,库藏股数量为0股,较上月底均保持不变,未见新增发行或股份购回、注销或库藏情况。综上,翰森制药本月并无发行或回购股票,股本结构及已发行股份数量均保持稳定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680717785","title":"【券商聚焦】中信证券:国内医药板块业绩持续修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2680717785","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680717785?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:40","pubTimestamp":1793580014,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券发布2027年医疗健康行业投资策略,“十五五”开局之年,医药行业首次列为国家新兴支柱产业,紧随其后的价格机制优化改革 、支持创新药械高定价、以及推动商业医疗保险发展等行业增量改革政策趋势,叠加国内医药行业在创新领域集中兑现等产业内外催化因素驱动下,该机构看到2026H1国内医药板块业绩持续修复,尤其是创新药、创新器械等新兴产业板块。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994936","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","02096","IE00B031HY20.USD","LU0828237510.HKD","LU1794554557.SGD","01093","09996","LU0708995153.HKD","159938","LU1064131003.USD","01177","06996","LU0588546209.SGD","02273","01276","09926","06821","00013","06030","LU0348825331.USD","09966","HK0000320264.USD","LU1969619763.USD","01548","BK0028","01951","03759","LU0607220059.USD","LU1226287529.USD","KCE","LU0348766576.USD","06078","02269","03692","LU0708995583.HKD","LU0455707207.USD","LU0823426480.USD","KURE","LU0979878070.USD","01952","02268","01530","600030","06990","02596","09939","02162","LU0039217434.USD","LU2488822045.USD","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157232716","title":"异动解读|翰森制药盘中上涨3.3%,创新药板块走强叠加ADC出海逻辑获关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1157232716","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157232716?lang=zh_cn&edition=full","pubTime":"2026-10-29 13:18","pubTimestamp":1793251110,"startTime":"0","endTime":"0","summary":"10月29日,翰森制药盘中上涨3.3%,报33.2港元,成交额1.96亿港元。此次异动主要与创新药板块延续强势有关,市场继续聚焦中国创新药出海主线,ADC、双抗等方向再获资金关注。公司此前与罗氏达成ADC战略合作及许可协议,涵盖两个临床前ADC项目及多个平台项目,翰森将获得4亿美元首付款、1.1亿美元一周年付款,并有资格获得逾150亿美元里程碑付款及销售分成。机构普遍认为,这进一步验证其ADC平台全球竞争力,并提升海外价值兑现能见度。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"翰森制药盘中上涨,ADC出海合作引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172651881","title":"异动解读|翰森制药盘中上涨3.02%,创新药板块走强叠加ADC出海逻辑获关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1172651881","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172651881?lang=zh_cn&edition=full","pubTime":"2026-10-28 11:24","pubTimestamp":1793157891,"startTime":"0","endTime":"0","summary":"10月28日,翰森制药盘中上涨3.02%,报32.8港元,成交额2.12亿港元。此次异动与创新药板块整体走强直接相关,市场继续关注中国创新药出海主线,ADC、双抗等赛道再获资金追捧。公司此前与罗氏达成ADC战略合作及许可协议,涵盖两个临床前ADC项目及多个平台项目,翰森将获得4亿美元首付款、1.1亿美元一周年付款,并有资格获得逾150亿美元里程碑付款及销售分成;多家机构认为,这进一步验证其ADC平台全球竞争力并提升海外价值兑现能见度。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"翰森制药盘中走强,ADC出海逻辑再获关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678243653","title":"创新药概念板块走强 恒瑞医药(01276)涨超11% 券商看好ADC、双抗等出海赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2678243653","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678243653?lang=zh_cn&edition=full","pubTime":"2026-10-28 10:32","pubTimestamp":1793154754,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念板块走强,截至发稿,恒瑞医药 涨11.14%,金斯瑞生物涨9.39%,康方生物涨4.70%,诺诚健华涨3.50%,欧康维视生物-B涨3.33%,亚盛医药涨2.65%,翰森制药涨2.32%。2026年,继续看好中国创新药出海的产业趋势,继续重点跟踪ADC、双抗、小核酸、减肥药等核心优势赛道的投资机会。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994616","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","06855","BK0196","KCE","LU1328615791.USD","09926","LU2476274720.SGD","03692","LU0348735423.USD","LU0359201885.HKD","BK0183","MEDX","IBBQ","IE00B5MMRT66.SGD","BK1191","BK1583","LU1655091616.SGD","LU1720050803.USD","LU2289578879.USD","LU0348767384.USD","LU1997245177.USD","LU0417516902.SGD","LU0417516738.SGD","LU2097828474.EUR","01548","01477","LU1781817850.SGD","HK0000320264.USD","LNGR","BK0188","LU1064130708.USD","BK1161","159992","LU0634319403.HKD","IE00B543WZ88.USD","LU1961090484.USD","09969","LU0405327148.USD","600276","LU0359201612.USD","LU1820825898.SGD","06978","KURE","LU0348827113.USD","LU0348783233.USD","LU0417516571.SGD","BK1576","LU2778985437.USD","01276","BK1589"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.1069},{"period":"1month","weight":-0.1059},{"period":"3month","weight":-0.0632},{"period":"6month","weight":-0.0752},{"period":"1year","weight":-0.1999},{"period":"ytd","weight":-0.1356}],"compareEarnings":[{"period":"1week","weight":-0.0519},{"period":"1month","weight":-0.0525},{"period":"3month","weight":-0.1384},{"period":"6month","weight":-0.1248},{"period":"1year","weight":-0.1326},{"period":"ytd","weight":-0.1256}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"翰森制药集团有限公司是一家主要从事一系列药品的研发、生产及销售的投资控股公司。该公司的创新药产品包括阿美乐、豪森昕福、迈灵达、孚来美、恒沐、昕越、圣罗莱等产品。该公司的创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统(CNS)疾病、代谢及其他治疗领域。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.002579},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.012814},{"month":3,"riseRate":0.428571,"avgChangeRate":0.023358},{"month":4,"riseRate":0.571429,"avgChangeRate":0.033967},{"month":5,"riseRate":0.571429,"avgChangeRate":-0.005202},{"month":6,"riseRate":0.571429,"avgChangeRate":0.039399},{"month":7,"riseRate":0.625,"avgChangeRate":0.011392},{"month":8,"riseRate":0.75,"avgChangeRate":0.028858},{"month":9,"riseRate":0.625,"avgChangeRate":-0.028026},{"month":10,"riseRate":0.125,"avgChangeRate":-0.009001},{"month":11,"riseRate":0.625,"avgChangeRate":0.049251},{"month":12,"riseRate":0.571429,"avgChangeRate":0.016882}],"exchange":"SEHK","name":"翰森制药","nameEN":"HANSOH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰森制药,03692,翰森制药股票,翰森制药股票老虎,翰森制药股票老虎国际,翰森制药行情,翰森制药股票行情,翰森制药股价,翰森制药股市,翰森制药股票价格,翰森制药股票交易,翰森制药股票购买,翰森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}